Key Takeaways Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European ...

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment. The company ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) on April 3 and set a price target ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...

President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...

Needham analyst Gil Blum lowered the firm’s price target on Sarepta (SRPT) to $183 from $202 and keeps a Buy rating on the ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “sell” ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.72, a high estimate of $202.00, and a low estimate of $75.00. This current ...

With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. RSI indicators hint that the underlying stock may be ...

Mizuho says that while “any clinical hold is concerning,” the European Medicines Agency’s request to pause the three Elevidys studies will ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...